In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Travere Therapeutics (TVTX – Research Report), with a ...

Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...

Elizabeth E. Reed, Senior Vice President, General Counsel, and Corporate Secretary of Travere Therapeutics, Inc. (NASDAQ:TVTX), reported selling 8,000 shares of the company's common stock. The sale, ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115, ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Read Our Latest Stock Analysis on TVTX Travere Therapeutics Stock Down 0.5 % Shares of TVTX opened at $18.37 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to ...

Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Equities research analysts at Wedbush upped their FY2024 earnings per share (EPS) estimates for Travere Therapeutics in a note issued ...